Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
treatment of primary focal resection plus lymph node dissection combined with chemotherapy
and anti-programmed cell death 1(PD-1) for Oligometastasis of urothelial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University